Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer: a Prospective, Single-arm, Open Label, Exploratory Phase 2 Clinical Trial.

NCT04720807 is registered in ClinicalTrials.gov with Xinhua Hospital, Shanghai Jiao Tong University School of Medicine as lead sponsor.

NCT NCT04720807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04720807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer: a Prospective, Single-arm, Open Label, Exploratory Phase 2 Clinical Trial.
Lead sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase
Phase 2
Overall status
Unknown status
Start date
September 1, 2020
Completion date
September 30, 2023
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

platinum-resistant recurrent ovarian cancer